Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of sunitinib (S) plus irinotecan (CPT-11) in a phase II trial in terms of response rate (RR) and 6-months progression-free survival (6-PFS). We also reviewed the clinical evidence from all the trials with S in this setting published to date and summarized it in a meta-analysis.

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature / Grisanti, Salvatore; Ferrari, Vittorio Domenico; BUGLIONE DI MONALE E BASTIA, Michela; Agazzi, Giorgio M; Liserre, Roberto; Poliani, Pietro Luigi; Buttolo, Luciano; Gipponi, Stefano; Pedersini, Rebecca; Consoli, Francesca; Panciani, Pierpaolo; Roca, Elisa; Spena, Giannantonio; Triggiani, Luca; Berruti, Alfredo. - In: JOURNAL OF NEUROSURGICAL SCIENCES. - ISSN 0390-5616. - 63:4(2019), pp. 458-467. [10.23736/S0390-5616.16.03874-1]

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

POLIANI, Pietro Luigi;
2019-01-01

Abstract

Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of sunitinib (S) plus irinotecan (CPT-11) in a phase II trial in terms of response rate (RR) and 6-months progression-free survival (6-PFS). We also reviewed the clinical evidence from all the trials with S in this setting published to date and summarized it in a meta-analysis.
2019
Glioblastoma; Review; Sunitinib
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/162497
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact